renal cell carcinoma

Management Guidelines for Patients on Sunitinib

aboey — Mon, 03 Dec 2007 18:27:43 -0600

A paper outlining the management recommendations for the treatment of renal cell carcinoma has been published.

Positive results in patients with advanced renal cell carcinoma

harminka — Mon, 04 Jun 2007 10:55:29 -0500

GlaxoSmithKline (GSK) announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC). These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.

Sutent achieves first line EAU approval for kidney cancer

harminka — Thu, 22 Mar 2007 12:47:55 -0500

Sutent (sunitinib malate) has received a European Association of Urology (EAU) recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma (mRCC).

Bayer and Onyx announce pivotal Nexavar kidney cancer study

harminka — Thu, 11 Jan 2007 08:03:08 -0600